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pen accessAbstract Aim: The enzyme methionine synthase (MetS) is linked to the cancer pathogenesis dis-
orders such as myeloid leukemia, prostate and breast tumors. Inhibition of the biosynthesis of
methionine amino acid which provides the tumor nucleic acid with one carbon atom building units
occurred through the blocking of the natural substrate 5-methyltetrahydrofolate (MTHF) to bind
to its binding domain in MetS with the synthesized compounds in this article.
Design and methods: The target compounds were designed to interact with the binding site of
MTHF in much the same way as the substrate. The crystal structure of MTHF binding region from
human source has been deduced. A series of aromatic compounds was synthesized and docked sep-
arately into the MTHF binding site of the enzyme. Thermodynamic algorithms were done and com-
pared to the results obtained from the biological cell line assay.
Results: The cytotoxicity assay (in vitro) of the most potent compounds 2-hydroxymethyl-5-nitro-
1H-benzimidazole and 1,3,5-trinitrobenzene showed IC50 of 50 ± 5 and 49 ± 5 lM, respectively,
with score of the lowest free energy of binding 1610.42 and 1737.10 kJ/mol, respectively.
Conclusion: The results of this study had led to the identiﬁcation of two lead compounds with good
inhibitory activities that could overlay for the next generation of the inhibitors for methionine syn-
thase. Preparation of novel potential inhibitors for the methionine synthase that have the ability to
avoid the side effects of the other marketed anticancer drugs could be a good step forward towards
cancer treatment.
ª 2011 Faculty of Pharmacy, Cairo University. Production and hosting by Elsevier B.V.
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Methionine synthase (MetS) (5-methyltetrahydrofolate-homo-
cysteine transmethylase) is one of two established mammalian
enzymes that utilize a biologically active cobalamin derivative
[methylcobalamin(CH3-Cbl)] as a cofactor.
1 MetS catalyzes
the transfer of the methyl group from 5-methyltetrahydrofo-
late to homocysteine via the CH3-Cbl cofactor, with cycling
of cobalamin between the +1 [Cbl(I)] and +3 [Cbl(III)]
oxidation states (Fig. 1). Studies on the human liver
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Figure 1 The cobalamin-dependant methionine synthase catalyzed reaction.35 The ﬁgure represents a part of the folic acid cycle in which
methionine synthase catalyzes the transmethylation from MTHF to homocysteine to produce methionine and tetrahydrofolate via using
cobalamin cofactor (CH3-Cbl, CH3-Cb(III)).
26 H.A. Ahmedcobalamin-dependent MetS have revealed that it is a large,
conformationally ﬂexible protein, consisting of four functional
domains arranged in a linear manner. Each one of these
domains binds a different substrate or cofactor. In detail, the
N-terminal module is the homocysteine (Hcy)-binding domain;
the second domain binds 5-methyltetrahydrofolate, the third
domain binds CH3-Cbl; and the fourth domain (C-terminal
module) binds S-adenosyl-methionine (S-AdoMet), an alloste-
ric cofactor required for reductive reactivation.2 X-ray crystal
structures of the cobalamin, S-AdoMet and 5-methyltetrahy-
drofolate-binding sites have only been reported for the human
enzyme.3–5 The reaction products methionine and tetrahydro-
folate are further metabolized through the one-carbon methio-
nine transmethylation and folate cycles. MetS is therefore
intimately linked to important biochemical pathways. These
include the reactions of biological methylations of DNA, lipids
and proteins, and polyamine through the production of methi-
onine and S-AdoMet.6,7 Furthermore, MetS is the only human
enzyme that metabolizes methyltetrahydrofolate to tetrahy-
drofolate, thereby facilitating the recycling of this major form
of folates to other bioactive folates that provide one-carbon
units for purine and pyrimidine synthesis. Impaired function
of MetS has been linked to megaloblastic anaemias and neuro-
logical disorders,8 atherosclerosis9 and carcinogenesis.10,11
Although the need to develop inhibitors of MetS as drug
candidates has long been recognized,12 there are a limited
number of reports on agents inhibiting this enzyme.
The anaesthetic gas N2O is possibly the only selective inhib-
itor of MetS reported to date, its action mediated through theoxidation of the cobalamin cofactor.13 Other compounds that
have been shown to inhibit this enzyme are the cell-signaling
molecule nitric oxide,14,15 chloroform and carbon tetrachlo-
ride,16 methylmercury,17 ethanol and acetaldehyde,18 hydra-
zine,19 S-AdoMet derivatives20 and a series of cobalamin
analogs.21
Polyamines have been shown to stimulate MetS activity,22
while methotrexate has been shown to indirectly inhibit the en-
zyme in vivo through depletion of its substrate, 5-methyltetra-
hydrofolate.23 In a new strategy for discovering speciﬁc
inhibitors of MetS, drug-like, aromatic compounds that mimic
substructures of 5-methyltetrahydrofolate have been evaluated
in a cell-free system (Table 3). The inhibitory activity and mech-
anism of action have been probed by kinetic studies using puri-
ﬁed rat liver enzyme, while a structure–activity relationship
study has been discerned using a model of the 5-methyltetrahy-
drofolate-binding site constructed by homology modeling.23
2. Experimental methods
2.1. Molecular modeling
Molecular modelling was carried out on Schrodinger computa-
tional software workstation using Maestro 7.5 graphic user
interface (GUI) and Red Hat Linux nash Enterprise version
V 4.1.18 on Batchmin V 9.1 modeling engine. Atomic coordi-
nates of the polypeptide segments of MTHF and Hcy binding
domains of MetS enzyme extracted from human liver were
obtained as a dimer from the protein bank database [PDB]
Figure 2 Crystal structure of MTHF docked in its binding receptor of MetS. The ﬁgure represents MTHF (yellow) docked in to its
binding receptor of MetS where the amino acids of the receptor (green) distributed around it. MTHF makes hydrogen bonds with aspartic
acid 473, asparagine 411, arginine 516.
Molecular modeling and synthesis of certain substituted 27(Brookhaven protein database). Explicit calcium ion counter
ions were included instead of cadmium and positioned at a
4 A˚ distance from the homocysteine binding site and this coun-
ter ion was added twice. The basic and acidic amino acids were
neutralized at pH 7 ± 2 by protonation of the terminal amino
groups of the amino acids and basic amino acids such as histi-
dine, lysine and arginine. Moreover, the terminal carboxylic
acid groups of amino acids and acidic amino acids such as glu-
tamic acid, aspartic acid, asparagine and glutamine were
deprotonated. Prime 1.5 was used to check the energy content
of the protein segments and loops. The ligands were docked in
to the MTHF binding domain as much the same way of con-
ﬁguration as the MTHF docked in the crystal structure ob-
tained from PDB (Fig. 2). Each ligand–MTHF receptor
complex was minimized using the conjugate gradients algo-
rithm until an energy convergence criterion of 0.1 kJ/mol
was reached with iteration cycle of 10,000. Molecular dynam-
ics (MD) at 300 K were then performed on the solvated system
for a 10 ps equilibration and 100 ps of production employing a
1-fs time step using OPLS 2005 (Optimized Potentials for Li-
quid Simulations force ﬁeld 2005) force ﬁeld, from which 100
structures were sampled at 1 ps intervals and averaged. The ﬁ-
nal averaged structure was then ﬁnally minimized.24
2.2. Chemical procedures
2.2.1. Materials and methods
All reagents were purchased from Aldrich, Lancaster Synthesis
or Avocado unless otherwise stated. All solvents were pur-
chased from Fisher and were of technical grade with the excep-
tion of dichloromethane and acetone, which were HPLC
grade.
Melting points were determined using Gallenkamp
apparatus.
Nuclear magnetic spectroscopy (NMR); 1H and 13C NMR
spectra were recorded using a JEOL GX600 spectrometer at600 MHz. Chemical shifts were referenced to tetramethylsilane
(TMS) as an internal reference at 0 ppm unless otherwise sta-
ted. Coupling constants are given in hertz (Hz). Additional
data are given where 13C assignments were made with the
assistance of DEPT 135 experiments. Deuterated solvents were
obtained from Goss Scientiﬁc Instruments. Deuterated chloro-
form was stored over 4 A˚ molecular sieves. DMSO and D2O
were stored in silica gel desiccators. For 1H NMR experiments,
typically sample (20 mg) was dissolved in the appropriate deu-
terated solvent (0.7 ml). For 13C NMR experiments, typically
sample (80 mg) was dissolved in the appropriate deuterated
solvent (0.7 ml). 13C NMR spectra of benzimidazole species
were obtained both in the absence and presence of a drop of
concentrated HCl added to the sample.
Infrared spectra (IR) of solid samples were recorded as KBr
discs using 5 mg of dry sample and 35 mg of dry KBr. Spectra
were recorded on a Nicolet 140 FTIR spectrophotometer in
the range 4000–400 cm1.
Mass spectra were acquired by electron impact using an
AEI MS902 mass spectrometer.
2.2.2. Experimental procedure
2.2.2.1. Synthesis of 2-aminomethyl-5-ﬂuro-1H-benzimidazole-
dihydrochloride [1]. 2-Aminomethyl-5-ﬂuro-1H-benzimid-
azoledihydrochloride was prepared using 4-ﬂuoro-1,2-
phenylenediamine (1.50 g, 0.012 mol) and glycine (1.13 g,
0.015 mol) dissolved in hydrochloric acid (60 ml, 5.5 M). The
reaction was heated under reﬂux for 216 h. The resulting
bright blue reaction mixture was left to crystallize at room
temperature. After 3-day bright blue crystals of 2-amino-
methyl-5-ﬂuro-1H-benzimidazoledihydrochloride25 (1.26 g,
44%) were recovered, m.p. 258–262 C.25
dH (DMSO-d6) 8.62 (2H, br s, NH2), 7.47 (1H, d,
3J 8.70, 7-
H), 7.25 (1H, dd, 3J 9.70, 4J 2.50, 4-H), 6.97 (1H, dd, 3J 9.20,
4J, 2.50, 6-H), 3.91 (2H, s, CH2), NH not observed; dC
(DMSO-d6) 164.2 (C-5), 149.1 (C-2), 134.1 (C-3a), 130.3
28 H.A. Ahmed(C-7a), 116.6 (C-7), 114.3 (C-6), 101.8 (C-4), 35.4 (C-10);
tmax/cm
1 (KBr) 3419 (N–H), 3050 (C–H, sp2), 2850 (C–H,
sp3), 1134 (C–F); MS (EI): m/z 165.1 (M+, 68%), 137.1 (85,
M+CHNH), 109.0 (20), 28.0 (39). Elemental analysis:
Found: C, 40.47%; H, 4.27%; N, 17.45%; C8H8N3F.2HCl:
Requires: C, 40.33%; H, 4.20%; N, 17.65%.
2.2.2.2. Synthesis of 2-aminomethyl-5-chloro-1H-benzimidazole
[2]. The same procedure [1] was applied for the preparation of
2-aminomethyl-5-chloro-1H-benzimidazole by using 4-chloro-
1,2-phenylenediamine (3.50 g, 0.025 mol) and glycine (2.25 g,
0.03 mol) dissolved in hydrochloric acid (40 ml, 5.5 M). The
mixture was heated under reﬂux for 216 h. The reaction mixture
was ﬁltered to remove a black solid which had formed during
the reaction. The ﬁltrate was left to evaporate slowly whereupon
2-aminomethyl-5-chloro-1H-benzimidazole (4.89 g, 77%) was
deposited as a brown solid, m.p. 251–252 C.
dH (DMSO-d6) 9.02 (2H, br s, NH2), 8.30 (1H, br s, NH),
7.76 (1H, d, 4J 2.00, 4-H), 7.68 (1H, d, 3J 8.70, 7-H), 7.32
(1H, dd, 3J 8.70, 4J 2.00, 6-H), 4.38 (2H, s, CH2); dC
(DMSO-d6) 144.8 (C-2), 132.4 (C-3a), 132.0 (C-7a), 130.2
(C-5), 127.7 (C-6), 115.8 (C-7), 114.5 (C-4), 34.4 (C-10);
tmax/cm
1 (KBr) 3500 (N–H), 3040 (C–H, sp2), 2890 (C–H,
sp3), 1840 (C–Cl); MS (ESI+): m/z 182.0 (M+, 100%),
148.0 (8), 116.0 (14).
2.2.2.3. Synthesis of 2-aminomethyl-5-methyl-1H-benzimidazole
dihydrochloride [3]. The same procedure [1] was applied for
the preparation of 2-aminomethyl-5-methyl-1H-benzimidazole
dihydrochloride by using 4-methyl-1,2-phenylenediamine
(12.22 g, 0.1 mol), and glycine (11.26 g, 0.1 mol) dissolved in
hydrochloric acid (70 ml, 5.5 M). The mixture was heated un-
der reﬂux temperature for 170 h. The reaction mixture formed
the blue solid of 2-aminomethyl-5-methyl-1H-benzimidazole
dihydrochloride (16.7 g, 71%) over several weeks, m.p. 208–
210 C.
dH (DMSO-d6) 9.57 (2H, br s, NH2), 8.37 (1H, br s, NH),
7.71 (1H, d, 3J 8.40, 7-H), 7.62 (1H, d, 3J 8.42, 4-H), 7.35
(1H, dd, 3J 8.40, 6-H), 4.56 (2H, s, CH2), 2.46 (3H, s, CH3);
dC (DMSO-d6) 142.6 (C-2), 138.4 (C-3a), 131.0 (C-7a), 128.9
(C-6), 128.8 (C-5), 113.8 (C-4), 113.6 (C-7), 34.1 (C-10), 20.9
(CH3); tmax/cm
1 (KBr) 3330 (N–H), 3055 (C–H, sp2), 2850
(C–H, sp3); MS (EI): m/z 161.4 (M+, 38%), 133.1 (18,
M+CHNH), 91.0 (5), 77.0 (6), 36.0 (100).
2.2.2.4. Synthesis of (S)-2-(1-aminoethyl)-5-methyl-1H-benz-
imidazole dihydrochloride [4]. The same procedure [1] was
applied for the preparation of (S)-2-(1-aminoethyl)-5-methyl-
1H-benzimidazole dihydrochloride by using 4-methyl-1,2-
phenylenediamine (6.34 g, 52.00 mmol) and l-alanine (5.46 g,
61.34 mmol) in hydrochloric acid (60 ml; 5.5 M). The mixture
was heated under reﬂux for 240 h. The resulting ﬁne blue
needles appearing on cooling of the reaction mixture were
washed with acetone (4 · 50 ml) to remove 4-methyl-1,2-phen-
ylenediamine. (S)-2-(1-Aminoethyl)-5-methyl-1H-benzimid-
azole dihydrochloride (9.32 g, 72%), m.p. 212–213 C.
dH (D2O) 7.65 (1H, d,
3J 8.90, 7-H), 7.58 (1H, d, 4J 1.00,
4-H), 7.45 (1H, dd, 3J 8.70, 4J 1.00, 6-H), 5.15 (1H, q, 3J
7.20, CH), 2.46 (3H, s, CH3), 1.89 (3H, d,
3J 7.20, CH3);
NHs not observed; dC (DMSO-d6) 149.9 (C-2), 136.6 (C-3a),
132.2 (C-7a), 130.1 (C-5), 128.1 (C-6), 114.6 (C-4), 114.3 (C-
7), 43.7 (C-10), 21.8 (CH3), 17.5 (C-8); tmax/cm
1 (KBr) 3050(C–H, sp2), 2830 (C–H, sp3), 1628 and 1450 (C‚C); MS
(EI): m/z 175.2 (M+, 45%), 160.1 (M+CH3), 131.1 (48,
M+CH3CHNH2), 118.1 (8), 77.0 (12).
2.2.2.5. Synthesis of (S)-2-(1-amino-2-phenylethyl)-1H-benz-
imidazole [5]. The same procedure [1] was applied for the
preparation of (S)-2-(1-amino-2-phenylethyl)-1H-benzimid-
azole was prepared by using 1,2-phenylenediamine (11.15 g,
0.103 mmol) was heated under reﬂux with phenylalanine
(22.01 g, 0.133 mmol) in hydrochloric acid (70 ml, 5.5 mmol)
for 216 h until untreated 1,2-phenylenediamine remained con-
stant in the reaction mixture. The reaction mixture was evap-
orated to dryness to give a bright blue solid. The impure
solid was dissolved in water and triethylamine (10 drops)
and extracted from ethyl acetate (3 · 10 ml). The resulting
sticky black tar was washed in boiling water (3 · 5 ml). Fine
white crystals of phenylalanine were recovered. The black tar
was further extracted from ethyl acetate followed by washing
with boiling water until (S)-2-(1-amino-2-phenylethyl)-1H-
benzimidazole was obtained as a yellow powder (5.25 g,
53%). m.p. 160–162 C.
dH (DMSO-d6) 7.75 (2H, dd,
3J 9.40, 4-H, 7-H), 7.46 (2H,
dd, 3J 9.40, 5-H, 6-H), 7.28 (5H, m, Ph), 5.09 (1H, q, 3J 7.42,
CH), 3.13 (2H, d, 3J 7.6.18, CH2); NHs not observed; dC
(DMSO-d6) 149 (C-2), 135.0 (C-9), 134.3 (C-3a, C-7a), 129.6
(C-13, C-11), 129.2 (C-14, C-10), 127.8 (C-12), 125.1 (C-5, C-
6), 115.1 (C-4, C-7); 49.5 (C-10), 38.0 (C-20).
2.2.2.6. Synthesis of 2-hydroxymethyl-5-nitro-1H-benzimidazole
[6]. The same procedure [1] was applied for the preparation of
2-hydroxymethyl-5-nitro-1H-benzimidazole by using 4-nitro-
1,2-phenylenediamine (8.00 g, 52 mmol) and glycolic acid
(10 ml, 50% w/v) which were dissolved in hydrochloric acid
(70 ml; 5.5 M) and the mixture was heated under reﬂux for
48 h. The reaction mixture was neutralized with ammonia
solution and the pink precipitate was recrystallized from water
after ﬁltering off any insoluble material. 2-Hydroxymethyl-5-
nitro-1H-benzimidazole was recovered as a yellow/brown
powder (5.31 g, 53%), m.p. 198–200 C.
dH (DMSO-d6) 8.38 (1H, d,
4J 2.22, 4-H), 8.10 (1H, dd, 3J
8.90, 4J 2.22, 6-H), 7.64 (1H, d, 3J 8.90, 7-H), 5.94 (1H, br s,
NH), 4.77 (2H, s, CH2), 3.39 (1H, br s, OH); dC (DMSO-d6)
160.3 (C-2), 144.1 (C-7a), 138.9 (C-5), 134.7 (C-3a), 119.8
(C-6), 115.2 (C-7), 111.5 (C-4), 56.9 (C-10); tmax/cm
1 (KBr)
3500 (O–H), 3450 (N–H), 3050 (C–H, sp2), 2850 (C–H, sp3),
1500 and 1350 (N–O) 1450 and 1350 (C–H, bend); MS (EI):
m/z 193 (M+, 100%), 164 (12, M–CHO), 147 (11), 129 (32),
90 (20), 63 (21). Elemental analysis: Found: C, 45.24%; H,
3.60%; N, 19.37%; C8H7N3O3: Requires: C, 45.45%; H,
3.58%; N, 19.88%.
2.2.2.7. Synthesis of 1,3,5-trinitrobenzene [7]. 1,3-Dinitroben-
zene (50 g, 0.297 mol) was dissolved in fuming nitric acid
(130.5 ml) and fuming sulphuric acid (243.5 ml), was then
heated under reﬂux at 150 C for 7 days. The reaction was
cooled slowly to room temperature. On addition to ice-cold
distilled water, a solid precipitated which was collected by ﬁl-
tration and recrystallized from glacial acetic acid to give
1,3,5-trinitrobenzene26 (40 g, 80%); m.p. 118–119 C.
dH (CDCl3) 9.41 (3H, s, 2-H, 4-H, 6-H). dC (CDCl3) 149.6
(C–NO2), 124.4 (CH–Ar). MS (EI):213 (M
+); tmax/cm
1
(KBr): 3104 (C–H, aromatic), 1475 (C‚C, aromatic), 1544
Table 1 Synthesized compounds with the corresponding IC50 of prostate cancer cell.
R1
N
N
H
R2
R1 R2 Yield (%) Compound IC50 (lM) of PC-3
CH2NH2 F 44 1 90 ± 5
CH2NH2 Cl 77 2 92 ± 5
CH2NH2 CH3 71 3 >250
CH2CH2NH2 CH3 72 4 >250
CHNH2CH2Ph H 53 5 89 ± 5
CH2OH NO2 53 6 50 ± 5
R3
R1R4
R2
R1 R2 R3 R4 Yield (%) Compound IC50 (lM) of PC-3
NO2 H NO2 NO2 80 7 49 ± 5
NO2 H OCH3 NO2 74 8 85 ± 5
NO2 NO2 OCH3 NO2 96 9 95 ± 5
NO2 NH2 OCH3 NO2 80 10 >250
The table represents the IC50 of different substituted heterocyclic compounds synthesized in this article and their yields. IC50, the half maximal
inhibitory concentration and is a measure of the effectiveness of a compound in inhibiting biological or biochemical function. This quantitative
measure indicates how much of a particular drug or other substance inhibitor is needed to inhibit a given biological process.
Molecular modeling and synthesis of certain substituted 29(N‚O, asymmetric), 1345 (N‚O, symmetric), 900 (C–H
bend). Elemental analysis: Found: C, 33.34%; H, 1.60%; N,
19.57%; C6H3N3O6: Requires: C, 33.82%; H, 1.42%; N,
19.72%.
2.2.2.8. Synthesis of 3,5-Dinitroanisole [8]. 1,3,5-Trinitroben-
zene (5 g, 0.023 mol) was dissolved in methanol (75 ml) with
gentle heating. To this hot solution, a hot solution of potas-
sium bicarbonate (7.5 g, 0.5 mol) in water (30 ml) and metha-
nol (20 ml) was added. The mixture was heated under reﬂux
for 2.5 h, cooled to room temperature and the methanol evap-
orated under reduced pressure. The aqueous residue was ex-
tracted with chloroform (3 · 40 ml), the chloroform extracts
combined, dried over MgSO4 and the solvent evaporated.
The product was recrystallized from ethanol to give 3,5-dini-
troanisole27 (3.36 g, 74%), m.p. 98–100 C.
dH (CDCl3) 8.65 (3H, s, 2-H, 4-H, 6-H), 4.01 (3H, s,
OCH3); dC (DMSO-d6): 164.3 (C-1), 152.7 (C-3, C-5), 118.9
(C-2, C-6), 114.3 (C-4), 61.07 (CH3); MS (EI): 198 (M
+);
tmax/cm
1 (KBr): 3098 (C–H, aromatic), 2862 (C–H, sp3),
1600 (C‚C, aromatic), 1544 (N‚O, asymmetric), 1345
(N‚O, symmetric), 1080 (C–O). Elemental analysis: Found:
C, 42.34%; H, 3.00%; N, 14.27%; C7H6N2O5: Requires: C,
42.43%; H, 3.05%; N, 14.14%.
2.2.2.9. Synthesis of 2,3,5-Trinitroanisole [9]. 3,5-Dinitroani-
sole (1.5 g, 0.007 mol) was dissolved in concentrated sulfuric
acid (20 ml) with gentle heating. The solution was placed in an
ice bath and fuming nitric acid (4 ml) was added dropwise over
a period of 10 min. The mixture was kept on ice for 20 min, with
constant stirring, and monitored by TLC. The reaction was
stopped by the addition of distilled water (50–100 ml) and the
product was extracted with ether (3 · 40 ml). The ether layerswere combined, dried over MgSO4 and the solvent evaporated.
The product was recrystallized from ethanol to give 2,3,5-trini-
troanisole26 (1.6 g, 96%), m.p. 100–104 C.
dH (CDCl3) 8.59 (1H, d,
4J 2, 4-H), 8.01 (1H, d, 4J 2, 6-H),
4.06 (3H, s, OCH3). dC (DMSO-d6) 155.1 (C-1), 152.5 (C-5),
143.9 (C-3), 140.0 (C-2), 116.5 (C-6), 107.4 (C-4), 60.2 (CH3);
MS (EI): 243 (M+); tmax/cm
1 (KBr): 3117 (C–H aromatic),
2992 (C–H, sp3), 1600m (C‚C, aromatic), 1469 (C‚C, aro-
matic), 1046 (C–O symmetric). Elemental analysis: Found:
C, 34.34%; H, 2.00%; N, 17.27%; C7H5N3O7: Requires: C,
34.58%; H, 2.07%; N, 17.28%.
2.2.2.10. Synthesis of 2-Amino-3,5-dinitroanisole [10]. 2,3,5-
Trinitroanisole (1 g, 0.004 mol) was dissolved in absolute eth-
anol (54 ml), cooled to 2 C, and concentrated NH3 (6 ml)
was added. The mixture was heated under reﬂux for 3 h,
cooled to room temperature and the solvent evaporated under
reduced pressure. After isolation by ﬂash chromatography
[chloroform/petroleum ether (70 · 30; v/v)], the product was
recrystallized from ethanol to give 2-amino-3,5-dinitroani-
sole28 (0.86 g, 80%), m.p. 182–184 C.
dH (CDCl3) 8.86 (1H, s, 4-H), 8.4 (1H, s, 6-H), 5.40 (2H, br
s, NH2), 4.05 (3H, s, OCH3); MS (EI): 214 (M
+); tmax/cm
1:
3465 (N–H, asymmetric), 3322 (N–H, symmetric), 3098 (C–
H, aromatic), 2992 (C–H, sp3), 1600 (C‚C, aromatic), 1550
(N‚O, asymmetric), 1450 (N‚O, symmetric), 1059 (C–O).
Elemental analysis: Found: C, 39.71%; H, 3.00%; N,
20.00%; C7H7N3O5: Requires: C, 39.44%; H, 3.31%; N,
19.71%.
2.2.3. Biological evaluation
Cell lines were supplied by the European Collection of Cell
Cultures (ECACC). PC-3: human prostate adenocarcinoma
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Figure 3 The docking pose of the synthesized compounds in this article (1-A), (2-B), (3-C), (4-D), (5-E) and (6-F) in MTHF binding
domain. Compound 2-aminomethyl-5-ﬂuro-1H-benzimidazole (gray and blue) in (A) makes hydrogen bonds with asparagine 508 and
glutamic acid 320; compound 2-aminomethyl-5-chloro-1H-benzimidazole (gray and blue) in (B) makes hydrogen bonds with asparagine
508 and glutamic acid 320; compound 2-aminomethyl-5-methyl-1H-benzimidazole (gray and blue) in (C) makes hydrogen bonds with
asparagine 411 and aspartic acid 473; compound (S)-2-(1-aminoethyl)-5-methyl-1H-benzimidazole (gray and blue) in (D) makes hydrogen
bond with aspartic acid 390; compound (S)-2-(1-amino-2-phenylethyl)-1H-benzimidazole (gray and blue) in (E) makes hydrogen bond
with aspartic acid 390 and compound 2-hydroxymethyl-5-nitro-1H-benzimidazole in (F) makes hydrogen bond with asparagine 411.
30 H.A. Ahmedcells were investigated. Cells were maintained in vitro at 37 C
in a 5% carbon dioxide, 95% air humidiﬁed incubator. Cells
were grown in RPMI media containing 100 lM of l-methio-
nine (abbreviated M+H) or methionine-free RPMI mediacontaining 100 lM of l-homocysteine thiolactone (abbreviated
MH+). Media was supplemented with 10% 1 kDa cut-off
dialyzed fetal calf serum (HL60, 20%), sodium pyruvate
(1 mM), l-glutamine (2 lM), Hepes (24 lM) and sodium
A B
C D
Arg 516 
Asn 323 
Asn 508 
Asp 390 
Asn 411 
Asp 473 
Asn 323 
Glu 320 
Asp 473 
Asn 411 
Asp 390 Asn 508 
Arg 516 
Glu 320 
Arg 516 
Asn 323 
Glu 320 
Asp 390 
Asn 411 
Asp 473 
Asn 508 
Arg 516 Asn 508 
Asp 473 
Asn 411 
Asp 390 
Asn 323 
Glu 320 
Figure 4 The docking pose of the synthesized compounds in this article (7-A), (8-B), (9-C), (10-D), in MTHF binding domain.
Compound 1,3,5-trinitrobenzene (gray and blue) in (A) makes hydrogen bond with asparagine 508; compound 3,5-dinitroanisole (gray
and blue) in (B) makes hydrogen bond with asparagine 508; compound 2,3,5-trinitroanisole (gray and blue) in (C) makes hydrogen bond
with asparagine 411 and compound 2-amino-3,5-dinitroanisole (gray and blue) in (D).
Molecular modeling and synthesis of certain substituted 31bicarbonate (2 lM). Cells in exponential growth were plated
(500–1000 · 103 cells per well) in complete M+H, medium,
containing l-methionine (100 lM). After an initial incubation
of 24 h at 37 C the medium was changed to MH and cells
were treated with compound concentrations between 100 and
0.1 lM. The tested compounds were dissolved in DMSO. After
a 24-h treatment the cells were washed twice with Hanks solu-
tion and transferred to fresh M+H medium (recovery). Cells
were then incubated for a further 5 days at 37 C before per-
forming the MTT assay. Cell culture media was collected at
appropriate times during recovery and stored at 80 C.
Appropriate control experiments were performed without the
inhibitors.
MTT (3-(4,5-dimethylthiazol-2-yl)2,5-diphenyltetrazolium
bromide) was used to assess the cytotoxicity of the tested com-
pounds in cell culture. Following the above described treat-
ments, media were recovered and the cells were treated with
fresh medium containing MTT (0.6 mg/ml). The cells were
incubated for 4 h at 37 C, the medium removed and replaced
with DMSO (150 ll) to dissolve the resulting crystals. The
absorbance of this solution was recorded at 550 nm in a plate
reader. The ﬁnal DMSO concentration was 0.1% and each
plate contained the blank group (complete medium 200 ll/welland no cells) and the control group (complete medium 200 ll/
well and untreated cells). After 96 h of exposure time, 20 ll of
MTT solution (5 mg/ml) was added and incubated in the dark
at 37 C for 4 h. The supernatant was removed and formazan
crystals were dissolved in DMSO (150 ll).29
The results of the IC50 values were listed down in Table 1.
3. Results
Compounds 6 and 7 showed the highest free binding energy
amongst the total synthesized compounds whereas compounds
5, 8 and 9 showed moderate free binding energies and the rest of
the synthesized compounds showed the lowest free binding en-
ergy. Nitro group was considered essential for the inhibition.
The lead compound should have a pharmacophore of a nitro
group attached to benzenoid ring either alone or fused to imid-
azole ring. Compounds 1 and 2 had the same docked poses in
the binding domain of MTHF but they are ﬂipped over where
ﬂuoride and chloride atoms pointed to the outermost part of
the receptor (Fig. 3A and B) compared to the docked natural
substrate (Fig. 2) and have RMSD value of 7.36 and 7.87 A˚,
respectively. The free binding energy of the docking for both
was 134.31 and 117.53 kJ/mol, respectively. Both of them
Table 2 The calculated energy terms for the interaction of a series of compounds synthesized in this article with MTHF binding
domain and their RMSD values.
Ligand Structure Energy term (kJ/mol) RMSD (A˚)
DEBind DEComplex DEReceptor DELigand
1
NH2
N
N
H
F 134.31 542.43 462.31 54.19 7.36
2
NH2
N
N
H
Cl
117.53 144.98 125.83 98.38 7.87
3
NH2
N
N
H
H3C
118.81 198.93 175.83 95.71 8.19
4
CH3
NH2
N
N
H
H3C
119.81 137.93 124.03 105.91 8.49
5
NH2
N
N
H
80.55 170.29 126.59 36.85 6.12
6
OH
N
NH
N+
O
O-
1610.42 1403.60 165.44 372.86 1.56
7
N+
OO-
N+
O
O-
N+
O
O-
1737.10 1540.40 111.40 308.10 1.77
8
CH3
O
N+
O
O-
N+
O
O-
470.05 620.09 196.00 45.96 4.96
9
NH2
N+
O
O-
N+
O
O-
490.35 530.19 101.99 62.15 8.29
10
CH3
O
N+
O
O-N
+
O
O-
H2N
159.14 198.01 134.91 96.04 8.29
The table represents a collection of information about the binding algorithms of the different docked ligands in to the receptor.
DEBind, the free binding energy algorithm results from Eq. (1); DEComplex, the free binding energy of the ligand–receptor complex; DEReceptor, the
free binding energy of the receptor; DELigand, the free binding energy of the ligand.
RMSD, the root mean square deviation, is a frequently-used measure of the differences between values predicted by a model or an estimator and
the values actually observed from the thing being modeled or estimated. RMSD is a good measure of precise docking of the inhibitors compared
to the natural substrate.
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Table 3 Structure of the compounds synthesized in this article.
Compound Structure
Methyltetrahydrofolate(MTHF)
N
H
N
H
N
N
H2N
O CH3
H
N
H
N
O OHO
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O
1
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N
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N
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34 H.A. Ahmedmake hydrogen bonds with the same amino acids of the binding
domain asparagine 508 and glutamic acid 320 and their IC50 oc-
curred at moderate concentration (90 ± 5 and 92 ± 5 lM,
respectively). Compound 3 had the same docked poses like
compounds 1 and 2 but with methyl group pointed to the more
spaced in the pocket (Fig. 3C) with RMSD value of 8.19 A˚ and
its free binding energy of the docking was 118.81 kJ/mol and
its IC50 occurred at high concentration (>250 lM). Com-
pound 4 had a horizontal docked poses in the binding domain
of MTHF (Fig. 3D) with RMSD value of 8.49 A˚ and the free
binding energy of the docking was 119.81 kJ/mol its IC50 oc-
curred at high concentration (>250 lM). The docked con-
former of the compound 5 bend over itself along its rotamer
keeping the phenyl moiety of the ligand pointed away from
aspartic acid 390 (Fig. 3E). The free binding energy of the dock-
ing was 80.55 kJ/mol and its IC50 occurred at moderately
high concentration (89 ± 5 lM). Compound 6 was docked in
such away that the nitro group protruded into the surface of
the receptor and the core of the ligand was docked vertically in-
side the pocket and hydroxyl group made hydrogen bond with
asparagine 411 (Fig. 3F). Compound 7 was docked deep inside
the enzyme receptor where the nitro group of the ligand made
hydrogen bond with asparagine 508 (Fig. 4A). Compounds 6
and 7 showed the highest inhibitory action on the enzyme reac-
tion. Their IC50 occurs at low concentrations (50 ± 5 and
49 ± 5 lM, respectively) and their free energy of binding were
1610.42 and 1737.10 kJ/mol, respectively. Compounds 8
and 9 showed a moderate IC50 value of 85 ± 5 and
95 ± 5 lM, respectively, and their free energy of binding were
470.05 and 490.35 kJ/mol, respectively. Compound 8 was
docked horizontally inside the pocket making hydrogen bond
with asparagine 508 (Fig. 4B) while compound 9 stacked to
the peripheral of the binding domain and made a hydrogen
bond with asparagine 411 (Fig. 4C). Compound 10 was docked
in such a way that the methoxy group was pointed away in the
space between the asparagine 411 and aspartic acid 473
(Fig. 4D). Compound 10 showed a high IC50 value of >250
and its free energy of binding was 159.14 with RMSD value
of 8.29 A˚ (Table 2).
4. Discussion
The design of the target compounds was based on the motif of
MTHF. The ﬁrst group of synthesized compounds was based
on the structure mimic of the pteridine ring of MTHF. The
pteridine ring was replaced by either 1H-benzimidazole nu-
cleus or benzene ring. Nitro benzene derivatives were chosen
in order to explore whether the imidazo moiety of the 1H-
benzimidazole or the benzoid ring was essential for the inhib-
itory activity of the enzyme. Molecular modeling used in this
article mainly in determining the free energy of binding of
the newly synthesized compounds and exploring the optimum
and plausible parameters for the lowest energy requirements
for the binding. The same parameters used to calculate the free
binding enthalpies and the mode of docking relative to the
docking poses of MTHF.30 The ligands and the enzyme were
reﬁned and the ligands were docked in to the binding domain
of the enzyme. If the appropriate conformation of a molecule
of interest reasonably ﬁts the binding domain of the enzyme,
then the receptor–protein complex will have a lower energy
than the sum of the energies of the un-complexed proteinand molecule. A thermodynamic procedure was operated on
each ligand–receptor complex, the receptor and ligand alone.
The total free energy of binding calculated from the Eq. (1).
The free energy of binding for each compound was obtained
and compared to the biological data already available (% inhi-
bition in vitro assay system)31 and the root mean square devi-
ation value RMSD was calculated for each ligand and
compared to the RMSD value of MTHF. This comparison
gave a good indication about the binding efﬁciency of the
docked ligands in this article and how their docking deviated
from the docking mode of the MTHF and type of inhibition
we have got. Therefore if the RMSD is less than 2 A˚, this leads
to a competitive inhibition and if the value is higher than 2 A˚,
this will probably lead to a mixed inhibition or uncompetitive
inhibition.32 The free binding energy of the docking for each
ligand–receptor was calculated from Eq. (1) and if the value
is small that means the binding afﬁnity of the ligand to the
receptor is high and small concentrations (IC50) are required
to inhibit the enzyme reaction and therefore stop the cancer
cell from obtaining the required carbon units to build up its
DNA, proteins and enzymes.33 The binding domain of MTHF
is conﬁned by ﬁve amino acids: aspartic acid 390, asparagine
411, aspartic acid 473, asparagine 508 and arginine 516. Com-
pounds 6 and 7 showed the lowest free energy of binding and
lowest IC50. This match was attributed to the strong electro-
static interactions between the nitro groups present in com-
pounds 6 and 7 with the binding amino acids of the
receptor. Therefore the presence of the nitro groups conﬁrm
the high binding to the receptor and hence the inhibition of
the growth and multiplication of the cancer cells. The ﬂuoride
and chloride atoms attached to benzimidazole ring in com-
pounds 1 and 2 caused repulsive van der Waals interaction
with aspartic acid 473 which led to implausible binding pose
to the receptor and led to high total free energy of binding
and therefore relatively high concentrations of the ligand were
required to inhibit the enzyme reaction. The bulky methyl
groups attached to position 5 in compounds 3 and 4 caused
the binding amino acids of the receptor to move apart in order
to reduce the steric hindrance. Therefore the enormous free
binding energy caused implausible docking of the two ligands.
Compounds 4–5 showed a repulsive p–p stacking between the
phenyl ring attached to the side chain and the hydrophobic
amino acids deep inside the binding pocket therefore the ligand
started to bend over to minimize this repulsive nonpolar–polar
interaction and this accounted for the relatively high free en-
ergy of binding and IC50. The high free energy of binding
and IC50 for compounds 8, 9 and 10 possibly ascribed to the
bulky methoxy group. Apparently methoxy group pushed
down the polar amino acid asparagine 411.
DEBind ¼ DEComplex  ðDEReceptor þ DELigandÞ ð1Þ
A vast variety of inhibitors were designed through the
replacement of the hydrogen at the position-2 of the lead moi-
ety of nitrobenzene with various groups or with the fusion with
imidazole ring. Modiﬁcation of these side chains of 5-nitro-
benzimidazole could also be achieved to create further
structural diversity. Disconnection of benzimidazole gives a
1,2-phenylenediamine and a carboxylic acid. This allows for
structural diversity both on the imidazole and benzene sides
of benzimidazole. A vast variety of inhibitors could be de-
signed through the replacement of the hydrogen at the position
2 of the lead compound 5-nitrobenzimidazole. The use of
NH2
NH2
R2 O
HO
R1+
HClReflux
N
H
NR2
R1
R1
R2
CH2NH2, CH2CH2NH2, CHNH2CH2Ph, CH2OH
F, Cl, CH3, H, NO2
Scheme 1 The synthesis of benzimidazole derivatives.
Molecular modeling and synthesis of certain substituted 35various substituted 1,2-phenylenediamines creates variation on
the benzene ring whereas variation on the imidazole side chain
can be achieved through the use of various carboxylic acids.
There are literally thousands of commercially available car-
boxylic acids which could undergo reaction with 1,2-phenylen-
ediamines to form the corresponding benzimidazoles. There
are only a handful of 5-substituted 1,2-phenylenediamines,
many of which are expensive. However, functionality could
be introduced onto the benzene ring component of benzimid-
azole through electrophilic substitution such as nitration or
functional group alterations. Two schemes were synthesized
in this article and in both of them we tried to create the struc-
ture of the lead compounds that have the ability to block the
enzyme reaction which ultimately produces methionine aminoNO2O2N
HNO3/H2SO4
NO2O2N
NO2
CH3OH/KHCO3
Reflux
Reflux
NO2O2N
OCH3
HNO3/H2SO4
Reflux
O2N
O
Scheme 2 The synthesis ofacid (Schemes 1 and 2). Therefore our study suggested that
the lead compounds which required to inhibit the enzyme
reaction should have the pharmacophore nitrobenzenoid
moiety.
The mechanism for this reaction involves initial nucleo-
philic attack of one of the two amino groups of phenylendi-
amine on the protonated carbonyl carbon of the carboxylic
acid, followed by removal of one molecule of water. This
is followed by intra-molecular nucleophilic attack by the sec-
ond amino group on the carbonyl carbon which led to ring
closure and the loss of a second molecule of water. The acid
catalyst is essential for this reaction. Using acetic acid as an
example, the methyl group in acetic acid increases the elec-
tron density on the carbonyl carbon atom of the carboxylic
group by an inductive effect (+I) along the sigma bond. This
makes the carbonyl group less reactive towards electrophilic
addition of an amino group. Therefore, an acid catalyst such
as hydrochloric acid is required to activate this group by di-
rect protonation using the free lone pairs of electrons on the
carbonyl oxygen to facilitate the attack of the nucleophile
(Scheme 1).
Racemisation occurred during the synthesis of compounds
4 and 5 was examined by using a chiral shift reagent such as
europium tris[3-(heptaﬂuoro-propylhydroxymethylene)-(+)-
camphorate].34 This reagent is able to interact with the stereo-
genic center formed in compounds 4 and 5 to make physical
complexes, converting the enantiomeric mixture if present into
a mixture of diasteriomers which are different in the physical
characters and could be detected using ﬂash chromatography.
This process has showed that one enantiomer was obtained
and racemisation has not occurred.
We have chosen methionine-dependant cancer cells in
which the cancer cells are unable to grow in a methionine de-
pleted medium even when replaced with the immediate precur-NO2
CH3
NO2
NH3
CH3CH2OH
NO2O2N
OCH3
NH2
nitrobenzene derivatives.
36 H.A. Ahmedsor, homocysteine.35 MetS is over-expressed in the cancer cells
and without the enzyme the cancer cells could not survive.
Therefore we have chosen these cancer cells to insure that inhi-
bition of the MetS enzyme catalytic reaction will be fatal for
the growing of the cancer cells. Hence molecular modeling is
essential to reﬂect the cytotoxicity assay.Acknowledgments
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